申请人:Merck & Co., Inc.
公开号:EP0208961A2
公开(公告)日:1987-01-21
There are disclosed phospholipid analogs having the formula:
wherein:
Y represents, e.g., -O;
R represents, e.g., -(CH2)15CH3;
Z represents, e.g.,
X is, e.g., trimethylamine;
R2 and R3 can be the same or different and are independently, e.g.,
(a) hydrogen;
(b) hydroxy;
(c) unsaturated or saturated, unsubstituted or substituted C1-C4 alkyl group wherein the substituents are hydroxy, acetyloxy, sulfhydryl, fluoro;
(d) azido;
(e) amido;
(f) acetamido;
m is, e.g., 1; and
n is, e.g., 2.
These compounds inhibit PAF (platelet-activating factor) biosynthesis and are thereby useful In the treatment of various diseases or disorders mediated by the PAF such as, for example, pain, fever, inflammation, cardiovascular disorder, asthma, lung edema, allergic disorders, skin diseases, psoriasis, and adult respiratory distress syndrome.
已公开的磷脂类似物具有以下式子:
其中
Y 代表,例如,-O;
R 代表,例如,-(CH2)15CH3;
Z 代表,例如
X 代表三甲胺等;
R2 和 R3 可以相同或不同,且各自独立,如
(a) 氢
(b) 羟基
(c) 不饱和或饱和、未取代或取代的 C1-C4 烷基,其中取代基为羟基、乙酰氧基、巯基、氟基;
(d) 叠氮
(e) 氨基
(f) 乙酰氨基;
m 是,例如 1;以及
n 是,例如 2。
这些化合物可抑制 PAF(血小板活化因子)的生物合成,因此可用于治疗由 PAF 介导的各种疾病或紊乱,例如疼痛、发热、炎症、心血管疾病、哮喘、肺水肿、过敏性疾病、皮肤病、牛皮癣和成人呼吸窘迫综合征。